Cargando…

Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors

Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawicka-Gutaj, Nadia, Komarowska, Hanna, Gruszczyński, Dawid, Derwich, Aleksandra, Klimont, Anna, Ruchała, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572558/
https://www.ncbi.nlm.nih.gov/pubmed/36233428
http://dx.doi.org/10.3390/jcm11195563
_version_ 1784810645183528960
author Sawicka-Gutaj, Nadia
Komarowska, Hanna
Gruszczyński, Dawid
Derwich, Aleksandra
Klimont, Anna
Ruchała, Marek
author_facet Sawicka-Gutaj, Nadia
Komarowska, Hanna
Gruszczyński, Dawid
Derwich, Aleksandra
Klimont, Anna
Ruchała, Marek
author_sort Sawicka-Gutaj, Nadia
collection PubMed
description Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level in discriminating between ACC and benign adrenocortical tumors. Twenty-two patients with ACC and twenty-six patients with benign adrenocortical tumors were recruited. Fasting blood samples were collected from each patient, and visfatin serum levels were measured with the ELISA Kit. Clinical stage, tumor size, Ki67 proliferation index, hormonal secretion pattern, and follow-up were determined in ACC patients. Patients with ACC had significantly higher visfatin serum concentrations (7.81 ± 2.25 vs. 6.08 ± 1.32 ng/mL, p-value = 0.003). The most advanced clinical stage with metastases was associated with significantly elevated visfatin levels (p-value = 0.022). Based on ROC analysis, visfatin serum concentrations higher than 8.05 ng/mL could discriminate ACC with a sensitivity of 50.0% and specificity of 92.3%. Univariate Cox regression indicated that tumor size was significantly related to shorter survival, and the visfatin level was borderline significant in all patients (HR = 1.013, p-value = 0.002, HR = 1.321, p-value = 0.058). In the Kaplan-Meier method, patients with visfatin serum concentrations higher than 6.3 ng/mL presented significantly lower survival probability (p-value = 0.006). Serum visfatin/NAMPT could be a potential risk predictor for the malignancy of adrenal tumors. However, further studies are needed on this subject.
format Online
Article
Text
id pubmed-9572558
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95725582022-10-17 Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors Sawicka-Gutaj, Nadia Komarowska, Hanna Gruszczyński, Dawid Derwich, Aleksandra Klimont, Anna Ruchała, Marek J Clin Med Article Adrenocortical carcinomas (ACC) are rare endocrine malignancies, often with a poor prognosis. Visfatin/NAMPT regulates a variety of signaling pathway components, and its overexpression has been found in carcinogenesis. Our study aimed to assess the clinical usefulness of visfatin/NAMPT serum level in discriminating between ACC and benign adrenocortical tumors. Twenty-two patients with ACC and twenty-six patients with benign adrenocortical tumors were recruited. Fasting blood samples were collected from each patient, and visfatin serum levels were measured with the ELISA Kit. Clinical stage, tumor size, Ki67 proliferation index, hormonal secretion pattern, and follow-up were determined in ACC patients. Patients with ACC had significantly higher visfatin serum concentrations (7.81 ± 2.25 vs. 6.08 ± 1.32 ng/mL, p-value = 0.003). The most advanced clinical stage with metastases was associated with significantly elevated visfatin levels (p-value = 0.022). Based on ROC analysis, visfatin serum concentrations higher than 8.05 ng/mL could discriminate ACC with a sensitivity of 50.0% and specificity of 92.3%. Univariate Cox regression indicated that tumor size was significantly related to shorter survival, and the visfatin level was borderline significant in all patients (HR = 1.013, p-value = 0.002, HR = 1.321, p-value = 0.058). In the Kaplan-Meier method, patients with visfatin serum concentrations higher than 6.3 ng/mL presented significantly lower survival probability (p-value = 0.006). Serum visfatin/NAMPT could be a potential risk predictor for the malignancy of adrenal tumors. However, further studies are needed on this subject. MDPI 2022-09-22 /pmc/articles/PMC9572558/ /pubmed/36233428 http://dx.doi.org/10.3390/jcm11195563 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sawicka-Gutaj, Nadia
Komarowska, Hanna
Gruszczyński, Dawid
Derwich, Aleksandra
Klimont, Anna
Ruchała, Marek
Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title_full Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title_fullStr Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title_full_unstemmed Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title_short Serum Visfatin/NAMPT as a Potential Risk Predictor for Malignancy of Adrenal Tumors
title_sort serum visfatin/nampt as a potential risk predictor for malignancy of adrenal tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572558/
https://www.ncbi.nlm.nih.gov/pubmed/36233428
http://dx.doi.org/10.3390/jcm11195563
work_keys_str_mv AT sawickagutajnadia serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors
AT komarowskahanna serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors
AT gruszczynskidawid serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors
AT derwichaleksandra serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors
AT klimontanna serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors
AT ruchałamarek serumvisfatinnamptasapotentialriskpredictorformalignancyofadrenaltumors